Fig. 4. Analysis of T cell responses according to treatment and in peptide-treated C-peptide responders and nonresponders. Analysis of T cell responses.

Slides:

Advertisements

Similar presentations

Epigenetic modifications and improved regulatory T-cell function in subjects undergoing dual sublingual immunotherapy Ravi S. Swamy, MD, Neha Reshamwala,

Advertisements

Fig. 4. PVSRIPO infection of DCs is sublethal, is marginally productive, and induces sustained proinflammatory cytokine production. PVSRIPO infection of.

Circulating gluten-specific FOXP3+CD39+ regulatory T cells have impaired suppressive function in patients with celiac disease Laura Cook, PhD, C. Mee.

T-cell regulation during viral and nonviral asthma exacerbations

Fig. 4. NASH-driven fibrosis is partly TGF-β–dependent.

Fig. 5 Maraba induces antitumor T cell immunity.

Fig. 6 Bimodal treatment results in reduced tinnitus loudness and reduced TFI scores in human patients. Bimodal treatment results in reduced tinnitus loudness.

PVSRIPO-mediated APC activation occurs in immunosuppressive conditions

Fig. 1 pDCs infiltrate the skin of SSc patients and spontaneously secrete IFN-α and CXCL4. pDCs infiltrate the skin of SSc patients and spontaneously secrete.

Fig. 8. mRIPO elicits neutrophil influx followed by DC and T cell infiltration into tumors. mRIPO elicits neutrophil influx followed by DC and T cell infiltration.

Fig. 3 BX795 blocks the synthesis of HSV-1 virions.

Fig. 7. The PD-L1 defect is evident in HSPCs from T1D patients.

Fig. 2. GPC3 expression in normal and tumor tissues.

Fig. 5. Immunohistochemistry of the tumor microenvironment in GBM specimens before and after CART-EGFRvIII infusion. Immunohistochemistry of the tumor.

Expression of CD36 and psap in a TMA of human ovarian cancer patients

Increased ADMA in pregnancy is associated with SGA birth outcomes

Fig. 4. Geographic atrophy progression in CFI risk-allele carriers and risk-negative subpopulations after monthly lampalizumab treatment. Geographic atrophy.

Fig. 1. Serum HBsAg, HBcrAg, and HBeAg reduction in human patients treated with a single dose of ARC-520. Serum HBsAg, HBcrAg, and HBeAg reduction in human.

Volume 138, Issue 2, Pages e4 (February 2010)

Katherine G. MacDonald, BSc, Nicholas A. J

Fig. 5. Serum VEGF-C correlates with antitumor immune responses and PFS after immunotherapy in human metastatic melanoma patients. Serum VEGF-C correlates.

Tregs and APC subsets in TDLNs of patients with cervical cancer.

Fig. 3 In situ vaccination with CpG and anti-OX40 is therapeutic in a spontaneous tumor model. In situ vaccination with CpG and anti-OX40 is therapeutic.

Fig. 3 Liver stiffness and NT-proBNP concentration after treatment with miridesap followed by dezamizumab. Liver stiffness and NT-proBNP concentration.

Allospecific Tregs Expanded After Anergization Remain Suppressive in Inflammatory Conditions but Lack Expression of Gut-homing Molecules Eleni Kotsiou,

Persistence of CAR4 cells is reduced after sustained TCR engagement

Fig. 5. Accelerated NASH-driven fibrogenesis in obese IFN-γ−/− mice is characterized by severe eosinophilic inflammation during TGF-β blockade. Accelerated.

Figure 3 Responder subset (A) Percentage of “responders” (nonprogressing patients) at week 25 after 6 months of treatment; percentage of “responders” in.

Volume 39, Issue 4, Pages (October 2003)

Fig. 8 Combining M7824 with radiation or chemotherapy enhances antitumor efficacy. Combining M7824 with radiation or chemotherapy enhances antitumor efficacy.

Fig. 5 Local gel scaffold for T cell memory response.

Fig. 2 Fas controls IL-1RA–sEV secretion in murine MSCs.

IL-33 treatment improves restorative macrophages (MΦ) but not function

Fig. 7 CSPG4-high GBMs show more microglia than CSPG4-low GBMs and express TNFα. CSPG4-high GBMs show more microglia than CSPG4-low GBMs and express TNFα.

Fig. 4 TNF-α up-regulates Fas/Fap-1 expression to promote IL-1RA–sEV release in murine MSCs. TNF-α up-regulates Fas/Fap-1 expression to promote IL-1RA–sEV.

Fig. 1 CpG induces the expression of OX40 on CD4 T cells.

Fig. 6. pKL cells revert hyperglycemia in NOD mice in vivo.

Fig. 7 DMN-Tre labeling of Mycobacterium tuberculosis is inhibited by tuberculosis drug cocktail, unlike auramine staining. DMN-Tre labeling of Mycobacterium.

TLR9 deficiency promotes aberrant T cell and myeloid dendritic cell (DC) phenotype in imiquimod-induced autoimmunity. TLR9 deficiency promotes aberrant.

Volume 123, Issue 4, Pages (October 2002)

Fig. 2. IL-2/rapamycin–expanded T cells express homing receptors to traffic to lymphoma sites and are resistant to SN-38 toxicity. IL-2/rapamycin–expanded.

Fig. 4. The effect of single-dose rozanolixizumab on the concentration of IgG subtypes in healthy subjects. The effect of single-dose rozanolixizumab on.

Differentiation stage determines pathologic and protective allergen-specific CD4+ T-cell outcomes during specific immunotherapy Erik Wambre, PhD, Jonathan.

Fig. 2. Exposure of both TCR and CAR antigens diminishes efficacy of CAR8 but not CAR4 cells. Exposure of both TCR and CAR antigens diminishes efficacy.

CD facilitates RCT in vivo and promotes urinary cholesterol excretion

Bexarotene is neuroprotective in mouse and human HD neurons in vitro

Fig. 3 CSF1 is expressed in human melanoma.

Fig. 1. Exposure to P. duboscqi uninfected sand flies (USFs) induces an anti-saliva immunity that protects NHP from vector-transmitted CL. Exposure to.

Vaccination induces activation of cTFH cells and transient ASCs

Fig. 5 BRD0705 induces differentiation in AML cell lines and primary patient samples through GSK3α-selective inhibition. BRD0705 induces differentiation.

Fig. 5 Treatment with an OX40 agonist antibody of 3-week-old HBVtgRag−/− mice or mice with chronic HBV disease results in an altered immune response to.

Fig. 2 CD32+ cells have a distinctively different phenotype compared to CD32− cells. CD32+ cells have a distinctively different phenotype compared to CD32−

IL-6 neutralization results in induction of CD161+ FOXP3+ CD127– Tregs in EC–CD4+ T cell cocultures. IL-6 neutralization results in induction of CD161+

Figure 2 CD4+ T-cell subsets fluorescence-activated cell sorting analysis in peripheral blood mononuclear cells of patients with multiple sclerosis treated.

Donor and recipient BAL T cells are phenotypically and functionally memory T cells. Donor and recipient BAL T cells are phenotypically and functionally.

No difference in T-cell response between SLE patients and healthy controls upon superantigen stimulation. No difference in T-cell response between SLE.

Fig. 4. PVSRIPO infection of DCs is sublethal, is marginally productive, and induces sustained proinflammatory cytokine production. PVSRIPO infection of.

BMS blocks functional responses in primary immune cells driven by IFNα

Fig. 4. Long-term persistence of CTL019 cells and polyfunctionality in patients achieving CR. Long-term persistence of CTL019 cells and polyfunctionality.

Volume 39, Issue 5, Pages (November 2013)

Antigen-specific CD8+ T cells express higher levels of PD-1 in animals that received the optimized SSX2 vaccine. Antigen-specific CD8+ T cells express.

ALT-803 stimulates proliferation and activation of human NK cells and T cells in vitro. ALT-803 stimulates proliferation and activation of human NK cells.

Treg expression of Gata3 plays a major role in controlling dermal fibrosis. Treg expression of Gata3 plays a major role in controlling dermal fibrosis.

Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia by David L. Porter, Wei-Ting.

Blood Tfr cells are immature but are not committed in the thymus.

Fig. 5 IL-5–mediated signaling is critical for the development of CD1dintCD5+ Breg precursor cells and IL-10+ Breg cells. IL-5–mediated signaling is critical.

Memory phenotypes PBMC-derived MERS-CoV-specific T cells from CWs

E2 induces IL-17–producing γδ+ T cells in the FGT

Low initial levels of CD4+ Tregs, proliferating CD8+, and Granzyme B+ CD8+ T cells and high posttreatment tumor MHC class II expression predict better.

Immunization with IR or F/T elicits activated OT-I cells of distinct phenotypes. Immunization with IR or F/T elicits activated OT-I cells of distinct phenotypes.

Presentation transcript:

Fig. 4. Analysis of T cell responses according to treatment and in peptide-treated C-peptide responders and nonresponders. Analysis of T cell responses according to treatment and in peptide-treated C-peptide responders and nonresponders. (A) Cumulative mean CD4 T cell IL-10 and IFN-γ responses to proinsulin stimulation measured over the duration of the 6-month treatment period shown according to treatment group. (B) Mean CD4 T cell IL-10 and (C) IFN-γ responses to proinsulin stimulation measured at each month during therapy in peptide-treated subjects divided according to C-peptide responder status. Bars and symbols represent mean stimulation index (SI) at each time point, and error bars are the 95% confidence intervals (CI). For analysis over the treatment period, longitudinal measurements of the SI were transformed using the natural logarithm (“Ln”) and were analyzed with linear models having visit and treatment as main factors and a repeated-measures error structure. Estimates of the mean SI across visits were computed using model-based estimates (least-squares means). (D) Change in FOXP3 expression levels [mean fluorescence intensity (MFI)] on all Treg subsets (CD4+CD25hiFOXP3+), (E) on memory (CD45RA−) adaptive Tregs, and (F) on memory CD39+ Tregs in peptide-treated subjects divided according to C-peptide responder status. (G) Change in Helios expression by Tregs in the same period and same groups. (H) Mean percentage levels of antigen-experienced (CD57+) CD8 T cells stained with peptide-HLA tetramers loaded with β cell peptides at baseline and at 6 months in peptide-treated C-peptide responders, compared with placebo and nonresponder subjects. Error bars show means and SEM. (B to H) C-peptide responders/nonresponders defined as having a post-baseline value that is 100% or more of the baseline value of C-peptide AUC during the treatment period. There were 9 peptide-treated C-peptide responders (6 of 9 subjects in the low-frequency and 3 of 7 in the high-frequency groups) and 10 nonresponders. Mohammad Alhadj Ali et al., Sci Transl Med 2017;9:eaaf7779 Published by AAAS